---
title: "BillionToOne to Report Second Quarter 2026 Financial Results on August 5, 2026 | BLLN Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292764574.md"
description: "BillionToOne, Inc. (NASDAQ: BLLN) announced it will release its financial results for the second quarter ended June 30, 2026, after market close on August 5, 2026. The company will host a conference call at 1:30 pm PT / 4:30 pm ET to discuss these results. Analysts are invited to register in advance, and a live webcast will be available on the company's investor relations website."
datetime: "2026-07-15T04:05:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292764574.md)
  - [en](https://longbridge.com/en/news/292764574.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292764574.md)
generator: "portal-rs"
---

# BillionToOne to Report Second Quarter 2026 Financial Results on August 5, 2026 | BLLN Stock News

See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google

Add on Google

MENLO PARK, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that the Company plans to release its financial results for the second quarter ended June 30, 2026 after the market close on Wednesday, August 5, 2026. BillionToOne will host a conference call to discuss its financial results at 1:30pm Pacific Time / 4:30pm Eastern Time the same day.

Analysts planning to participate in the conference call should register here before the 1:30pm Pacific Time / 4:30pm Eastern Time start. A live and archived webcast for interested listeners will be available on the “Events” page of BillionToOne’s investor relations website at https://investors.billiontoone.com/.

**About BillionToOne**

Headquartered in Menlo Park, California, BillionToOne is a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all. The company's patented Quantitative Counting Templates™ (QCT™) molecular counting platform is the only multiplex technology that can accurately count DNA molecules at the single-molecule level. For more information, visit www.billiontoone.com.

**Investor Contact**  
ir@billiontoone.com

**Media Contact**  
billiontoone@moxiegrouppr.com

### Related Stocks

- [BLLN.US](https://longbridge.com/en/quote/BLLN.US.md)

## Related News & Research

- [Billiontoone (NASDAQ:BLLN) SVP Bosch John Roderick Ten Sells 1,416 Shares](https://longbridge.com/en/news/298775247.md)
- [BillionToOne General Counsel Thomas P. Lynch sells 19,962 Class A shares for $1.99 million](https://longbridge.com/en/news/298655496.md)
- [Ecosuntek adds Q3 KPI update to 2026 corporate events calendar](https://longbridge.com/en/news/298712114.md)
- [Annaly Capital declares Q3 2026 dividend of $0.75 per share](https://longbridge.com/en/news/298499808.md)
- [Benfica Futebol SAD corrects AGM date to Oct. 1, 2026 from Sept. 30, 2026](https://longbridge.com/en/news/298497181.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**